Clinical trial · Interventional
Neurocognitive Assessment CNSL and LGG
Neurocognitive Evaluation Using Digital Technology: A Pilot Study in Primary Central Nervous System Lymphoma and Low-grade Gliomas
NCT07710131CI-TRIAL-00118413not yet recruitingN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study is to determine whether self-administered digital cognitive tests can serve as accurate and reliable alternatives to established neuropsychological tests for evaluating cognitive functioning in participants with primary central nervous system lymphoma and low-grade gliomas.
Conditions
Conditions (5)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Brain Tumor | Brain Neoplasm | ALIAS | 0.90 |
| Cognitive Dysfunction | — | UNRESOLVED | — |
| IDH Mutation | — | UNRESOLVED | — |
| Low-grade Glioma | Low Grade Glioma | ONTOLOGY_EXACT | 0.98 |
| PCNSL | Primary Central Nervous System Lymphoma | ALIAS | 0.90 |
Interventions
Interventions (4)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Brain MRI (Standard of Care) | Other | — | UNRESOLVED |
| Digital Cognitive Assessment (TestMyBrain and Mobile Toolbox) | Behavioral | — | UNRESOLVED |
| Quality of Life and Mood Questionnaires | Other | — | UNRESOLVED |
| Traditional Neuropsychological Testing | Behavioral | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- OTHER
- label
- Digital Cognitive Assessment
- description
- Participants with newly diagnosed PCNSL or IDH-mutant LGG will undergo both traditional neuropsychological testing and digital cognitive assessments (TestMyBrain and Mobile Toolbox) at specified timepoints (baseline, 6 months, post-treatment or 12-14 months). Quality of life and mood questionnaires will also be administered. Brain MRI data will be collected as part of standard care. Participants will be sent a link to complete the digital cognitive tests at home. Questionnaires will also be sent via email to complete. Data will be collected from brain MRIs obtained as part of standard of care/routine surveillance. * Screening visit * Baseline visit (2- months) * Follow-Up visit (3-month) * End of Treatment 2 months after completing treatment (PCNSL only) * Final Assessment 12-14 months after baseline (LGG only). * Brain MRI (standard of care) based on participant permission There is no follow-up care as part of this research study.
- interventionNames
- Behavioral: Digital Cognitive Assessment (TestMyBrain and Mobile Toolbox)
- Behavioral: Traditional Neuropsychological Testing
- Other: Quality of Life and Mood Questionnaires
- Other: Brain MRI (Standard of Care)
Primary outcomes (3)
- measure
- Evaluating the Construct Validity of Digital Cognitive Tests
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Histopathologically confirmed newly diagnosed primary CNS diffuse large B-cell lymphoma (DLBCL) OR * Histopathologically confirmed IDH-M low grade glioma diagnosis in the past 12 months who have not started tumor directed therapy (if applicable). * Age ≥ 18 years. * Ability to consent to study. Exclusion Criteria: * Patients who have severe visual impairment that cannot be corrected with glasses to read regular sized print. * Patients who have known psychiatric or substance abuse disorders that would interfere with their cooperation in completing the requirements of the study.
References
Publications (0)
Data not yet available
No reference posted for this study.